| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| NAGENiagen Bioscience Inc | 503.58M | 6.31 | 57.36 | 19.18% | 16.38% | 28.91% | 2.37% | 0.06 |
| BTXBlackRock Technology and Private Equity Term Trust | 808.8M | 6.93 | 40.76 | -81.13% | 87.75% | 1.87% | 34.27% | |
| HALOHalozyme Therapeutics, Inc. | 8.45B | 71.82 | 20.94 | 22.44% | 47.91% | 118.17% | 5.55% | 4.14 |
| RPRXRoyalty Pharma plc | 16.97B | 39.72 | 20.80 | -3.86% | 32.55% | 7.95% | 16.32% | 0.74 |
| REGNRegeneron Pharmaceuticals, Inc. | 76.63B | 741.92 | 19.35 | 8.27% | 32.13% | 14.79% | 4.78% | 0.09 |
| GMABGenmab A/S | 20.85B | 33.85 | 2.79 | 30.67% | 46.8% | 114.25% | 36.37% | 0.03 |
| DNAGinkgo Bioworks Holdings, Inc. | 464.86M | 9.58 | -0.91 | -9.71% | -188% | -60.66% | 0.65 | |
| PRMEPrime Medicine, Inc. | 720.24M | 3.99 | -2.42 | -33.02% | -121.95% | 0.27 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Sales/Revenue | 2.06M | 4.78M | 4.78M | 5.75M | 5.72M | 4.53M |
| Revenue Growth % | - | 1.32% | 0% | 0.2% | -0.01% | -0.21% |
| Cost of Goods Sold | 0 | 11.45M | 44.59M | 58.91M | 47.57M | 62.46M |
| COGS % of Revenue | - | 2.39% | 9.32% | 10.25% | 8.32% | 13.78% |
| Gross Profit | 2.06M | -6.67M | -39.8M | -53.16M | -41.85M | -57.92M |
| Gross Margin % | 1% | -1.39% | -8.32% | -9.25% | -7.32% | -12.78% |
| Gross Profit Growth % | - | -4.24% | -4.97% | -0.34% | 0.21% | -0.38% |
| Operating Expenses | 8.32M | 6.63M | 35.43M | 53.59M | 73.67M | 50.96M |
| OpEx % of Revenue | 4.04% | 1.39% | 7.41% | 9.32% | 12.88% | 11.24% |
| Selling, General & Admin | 3.52M | 5.5M | 0 | 0 | 0 | 0 |
| SG&A % of Revenue | 1.71% | 1.15% | - | - | - | - |
| Research & Development | 4.31M | 11.45M | 44.59M | 58.91M | 48.07M | 63.86M |
| R&D % of Revenue | 2.09% | 2.39% | 9.32% | 10.25% | 8.41% | 14.08% |
| Other Operating Expenses | 491K | -10.32M | -9.15M | -5.32M | 25.6M | -12.9M |
| Operating Income | -6.26M | -13.3M | -75.24M | -106.75M | -115.52M | -108.89M |
| Operating Margin % | -3.04% | -2.78% | -15.73% | -18.57% | -20.2% | -24.02% |
| Operating Income Growth % | - | -1.12% | -4.66% | -0.42% | -0.08% | 0.06% |
| EBITDA | -5.77M | -12.17M | -68.58M | -93.71M | -101.52M | -95.5M |
| EBITDA Margin % | -2.8% | -2.55% | -14.34% | -16.31% | -17.75% | -21.06% |
| EBITDA Growth % | - | -1.11% | -4.64% | -0.37% | -0.08% | 0.06% |
| D&A (Non-Cash Add-back) | 491K | 1.13M | 6.65M | 13.04M | 14M | 13.39M |
| EBIT | -6.32M | -13.72M | -74.34M | -106.75M | -93.68M | -107.49M |
| Net Interest Income | -268K | -634K | -3.43M | -972K | -1.01M | -565K |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 268K | 634K | 3.43M | 972K | 1.01M | 565K |
| Other Income/Expense | -319K | -1.05M | -34.62M | 1.39M | 5.05M | 5.85M |
| Pretax Income | -6.58M | -14.35M | -109.86M | -105.36M | -110.47M | -103.04M |
| Pretax Margin % | -3.2% | -3% | -22.97% | -18.33% | -19.32% | -22.73% |
| Income Tax | 0 | 0 | -8.9M | -461K | 100K | 70K |
| Effective Tax Rate % | 1% | 1% | 0.92% | 1% | 1% | 1% |
| Net Income | -6.58M | -14.35M | -100.96M | -104.9M | -110.57M | -103.11M |
| Net Margin % | -3.2% | -3% | -21.11% | -18.25% | -19.34% | -22.74% |
| Net Income Growth % | - | -1.18% | -6.03% | -0.04% | -0.05% | 0.07% |
| Net Income (Continuing) | -6.58M | -14.35M | -100.96M | -104.9M | -110.57M | -103.11M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.07 | -0.54 | -1.11 | -1.15 | -1.20 | -0.94 |
| EPS Growth % | - | -6.33% | -1.06% | -0.04% | -0.04% | 0.22% |
| EPS (Basic) | -0.07 | -0.54 | -1.11 | -1.15 | -1.20 | -0.94 |
| Diluted Shares Outstanding | 92.25M | 92.25M | 92.65M | 90.85M | 92.03M | 110.24M |
| Basic Shares Outstanding | 92.25M | 92.25M | 92.65M | 90.85M | 92.03M | 110.24M |
| Dividend Payout Ratio | - | - | - | - | - | - |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 13.65M | 73.23M | 273.08M | 186.86M | 120.58M | 133.83M |
| Cash & Short-Term Investments | 13.09M | 69.87M | 252.57M | 164.43M | 97.66M | 112.42M |
| Cash Only | 13.09M | 69.87M | 252.57M | 59.95M | 72.36M | 41.21M |
| Short-Term Investments | 0 | 0 | 0 | 104.48M | 25.3M | 71.21M |
| Accounts Receivable | 222K | 1.59M | 1.43M | 1.55M | 2.19M | 0 |
| Days Sales Outstanding | 39.34 | 121.72 | 108.77 | 98.44 | 139.73 | - |
| Inventory | 0 | 0 | 10.51M | 15.02M | 0 | 0 |
| Days Inventory Outstanding | - | - | 86.06 | 93.08 | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 20.73M | 21.41M |
| Total Non-Current Assets | 5.82M | 15.34M | 153.12M | 134.15M | 96.72M | 79.78M |
| Property, Plant & Equipment | 5.01M | 13.38M | 58.65M | 58.04M | 45.82M | 33.13M |
| Fixed Asset Turnover | 0.41x | 0.36x | 0.08x | 0.10x | 0.12x | 0.14x |
| Goodwill | 0 | 0 | 21.34M | 21.34M | 0 | 0 |
| Intangible Assets | 283K | 0 | 54.99M | 51.62M | 48.25M | 44.88M |
| Long-Term Investments | 790K | 0 | 16.84M | 1.86M | 0 | 0 |
| Other Non-Current Assets | 531K | 1.95M | 18.14M | -16.38M | 2.65M | 1.76M |
| Total Assets | 19.47M | 88.57M | 426.19M | 321.01M | 217.3M | 213.61M |
| Asset Turnover | 0.11x | 0.05x | 0.01x | 0.02x | 0.03x | 0.02x |
| Asset Growth % | - | 3.55% | 3.81% | -0.25% | -0.32% | -0.02% |
| Total Current Liabilities | 3.47M | 10.1M | 33.86M | 30.27M | 29.56M | 28.66M |
| Accounts Payable | 268K | 2.12M | 8.38M | 2.41M | 1.5M | 3.53M |
| Days Payables Outstanding | - | 67.47 | 68.64 | 14.95 | 11.53 | 20.62 |
| Short-Term Debt | 1.2M | 1.53M | 2.4M | 2.95M | 3.26M | 2.73M |
| Deferred Revenue (Current) | 780K | 0 | 1000K | 445K | 1000K | 1000K |
| Other Current Liabilities | 0 | 2.63M | 0 | 0 | 12.75M | 12.75M |
| Current Ratio | 3.94x | 7.25x | 8.07x | 6.17x | 4.08x | 4.67x |
| Quick Ratio | 3.94x | 7.25x | 7.75x | 5.68x | 4.08x | 4.67x |
| Cash Conversion Cycle | - | - | 126.19 | 176.58 | - | - |
| Total Non-Current Liabilities | 57.16M | 11.47M | 26.23M | 16.32M | 11.56M | 5.82M |
| Long-Term Debt | 1.75M | 4.14M | 1.12M | 7.98M | 4.66M | 1.26M |
| Capital Lease Obligations | 2.38M | 6.58M | 12.2M | 8.07M | 5.64M | 4.43M |
| Deferred Tax Liabilities | 0 | 0 | 743K | 238K | 186K | 0 |
| Other Non-Current Liabilities | 53.03M | 749K | 12.16M | 35K | 109K | 133K |
| Total Liabilities | 60.63M | 21.56M | 60.09M | 46.59M | 41.12M | 34.48M |
| Total Debt | 6.02M | 14.5M | 20.01M | 22.98M | 15.88M | 10.11M |
| Net Debt | -7.07M | -55.37M | -232.56M | -36.97M | -56.48M | -31.11M |
| Debt / Equity | - | 0.22x | 0.05x | 0.08x | 0.09x | 0.06x |
| Debt / EBITDA | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - |
| Interest Coverage | -23.38x | -20.98x | -21.92x | -109.83x | -114.37x | -192.72x |
| Total Equity | -41.16M | 67M | 366.11M | 274.41M | 176.18M | 179.13M |
| Equity Growth % | - | 2.63% | 4.46% | -0.25% | -0.36% | 0.02% |
| Book Value per Share | -0.45 | 0.73 | 3.95 | 3.02 | 1.91 | 1.62 |
| Total Shareholders' Equity | -41.16M | 67M | 366.11M | 274.41M | 176.18M | 179.13M |
| Common Stock | 2K | 2K | 9K | 9K | 9K | 12K |
| Retained Earnings | -41.38M | -90.06M | -191.03M | -295.93M | -406.5M | -509.6M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -52.76M | 0 | -13K | -120K | -37K | -4K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Cash from Operations | -6.03M | -10.97M | -60.6M | -81.34M | -64.64M | -72.4M |
| Operating CF Margin % | -2.93% | -2.29% | -12.67% | -14.15% | -11.3% | -15.97% |
| Operating CF Growth % | - | -0.82% | -4.52% | -0.34% | 0.21% | -0.12% |
| Net Income | -6.58M | -14.35M | -100.96M | -104.9M | -110.57M | -103.11M |
| Depreciation & Amortization | 491K | 1.13M | 6.65M | 13.1M | 14M | 13.39M |
| Stock-Based Compensation | 42K | 420K | 10.61M | 12.54M | 11.42M | 19.45M |
| Deferred Taxes | 0 | 0 | -8.9M | -505K | -52K | 0 |
| Other Non-Cash Items | 108K | 824K | 35.15M | -30K | 19.05M | -1.77M |
| Working Capital Changes | -89K | 1.01M | -3.15M | -1.54M | 1.52M | -368K |
| Change in Receivables | -102K | -1.37M | 230K | -148K | -666K | 2.24M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 82K | 903K | 1.57M | -533K | -786K | 2.03M |
| Cash from Investing | -1.09M | -2.17M | -67.38M | -126.98M | 81.94M | -41.58M |
| Capital Expenditures | -1.1M | -2.18M | -38.05M | -16.18M | -860K | -404K |
| CapEx % of Revenue | 0.53% | 0.46% | 7.96% | 2.81% | 0.15% | 0.09% |
| Acquisitions | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - |
| Other Investing | 9K | 10K | 0 | 783K | 254K | 939K |
| Cash from Financing | 12.71M | 70.97M | 336.19M | 5.24M | -4.48M | 82.53M |
| Debt Issued (Net) | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - |
| Other Financing | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | - | - | - | - | - | - |
| Free Cash Flow | -7.13M | -13.15M | -98.64M | -97.51M | -65.5M | -72.81M |
| FCF Margin % | -3.46% | -2.75% | -20.63% | -16.97% | -11.45% | -16.06% |
| FCF Growth % | - | -0.84% | -6.5% | 0.01% | 0.33% | -0.11% |
| FCF per Share | -0.08 | -0.14 | -1.06 | -1.07 | -0.71 | -0.66 |
| FCF Conversion (FCF/Net Income) | 0.92x | 0.76x | 0.60x | 0.78x | 0.58x | 0.70x |
| Interest Paid | 202K | 508K | 652K | 895K | 970K | 561K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -111.07% | -46.62% | -32.76% | -49.08% | -58.04% |
| Return on Invested Capital (ROIC) | - | - | -77.73% | -43.16% | -48.52% | -61.01% |
| Gross Margin | 100% | -139.5% | -832.37% | -925.02% | -731.88% | -1277.57% |
| Net Margin | -319.61% | -300.27% | -2111.25% | -1825.37% | -1933.65% | -2274.06% |
| Debt / Equity | - | 0.22x | 0.05x | 0.08x | 0.09x | 0.06x |
| Interest Coverage | -23.38x | -20.98x | -21.92x | -109.83x | -114.37x | -192.72x |
| FCF Conversion | 0.92x | 0.76x | 0.60x | 0.78x | 0.58x | 0.70x |
| Revenue Growth | - | 132.04% | 0.04% | 20.18% | -0.5% | -20.71% |
Absci Corporation (ABSI) reported $2.8M in revenue for fiscal year 2024. This represents a 37% increase from $2.1M in 2019.
Absci Corporation (ABSI) saw revenue decline by 20.7% over the past year.
Absci Corporation (ABSI) reported a net loss of $114.6M for fiscal year 2024.
Absci Corporation (ABSI) has a return on equity (ROE) of -58.0%. Negative ROE indicates the company is unprofitable.
Absci Corporation (ABSI) had negative free cash flow of $81.9M in fiscal year 2024, likely due to heavy capital investments.